abstract |
The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, i.e., individuals with good prognosis; HG, i.e., individuals with poor prognosis of primary tumour; PrCa Met, i.e., individuals with poor prognosis and metastasis; and CRPC, i.e., individuals with poor prognosis suffering from aggressive localized disease. Specifically, the present invention relates to method for establishing the presence, or absence, of prostate cancer in a human individual comprising: a) determining the expression of one or more genes chosen from the group consisting of RRM2, HOXC6, TGM4, RORB, HOXDlO, SFRP2, and SNAI2 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising prostate tumour cells or prostate tumour tissue, or from an individual not suffering from prostate cancer; and c) establishing the presence, or absence, of prostate cancer based on the established up- or down regulation of said one or more genes. |